Beyond State Scope of Practice Laws for Advanced Practitioners

Additional Supervision Requirements for Buprenorphine Prescribing

Published in: Journal of Substance Abuse Treatment (2022). doi: 10.1016/j.jsat.2021.108715

Posted on on March 31, 2022

by Barbara Andraka-Christou, Adam J. Gordon, Joanne Spetz, Rachel Totaram, Matthew Golan, Olivia Randall-Kosich, Jordan M. Harrison, Spencer Calder, Stefan G. Kertesz, Bradley D. Stein

Read More

Access further information on this document at Science Direct

This article was published outside of RAND. The full text of the article can be found at the link above.

This study of state buprenorphine prescribing laws found that

  • one state prohibits all advanced practice clinicians from prescribing buprenorphine
  • five states require a waivered supervising physician for PAs prescribing buprenorphine
  • three states require a waivered supervising physician for NPs prescribing buprenorphine.

Studies of state NP/PA supervision should include non-scope of practice laws.

Research conducted by

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.